<DOC>
	<DOCNO>NCT00238979</DOCNO>
	<brief_summary>The aim study whether switch stable renal transplant recipient receive tacrolimus without corticosteroid mycophenolate mofetil ( MMF ) enteric-coated mycophenolate sodium ( EC-MPS ) safe well tolerated patient .</brief_summary>
	<brief_title>A Study Investigate Tolerability Safety Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With Without Corticosteroids From Mycophenolate Mofetil ( MMF ) Enteric-coated Mycophenolate Sodium ( EC-MPS )</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion : Recipients first secondary cadaveric heartbeating , live unrelated living relate kidney transplant . Currently receive 1 , 1.5 , 2 g MMF/day , tacrolimus without corticosteroid part immunosuppressive regimen least 3 month . In stable condition term graft function . Exclusion criterion : Patients take investigational drug within four week prior study entry History malignancy within last 5 year , except excise squamous basal cell carcinoma skin . Thrombocytopenia ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 and/or leukocytopenia ( &lt; 2,500/mm3 ) , and/or hemoglobin &lt; 6.0 g/dL prior enrollment Clinically significant infection require continued therapy , severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus , evidence severe liver disease , HIV Hepatitis B surface antigen positive . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Renal transplantation , Enteric-coated mycophenolate sodium</keyword>
</DOC>